Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now

Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer

Status: Recruiting
Phase: Phase 1
Diagnosis: Lung Cancer
NCT ID: NCT00264602 (View complete trial on
DFCI Protocol ID: 05-219


The primary purpose of this study is to determine if we can identify the first lymph node that drains from the tumor, and thus would be the most likely site for metastatic disease, and remove it for analysis to improve the ability to detect tumor in this node and to remove this additional site that potentially contains tumor cells.


Conducting Institutions:
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Beth-Israel Deaconess Medical Center

Overall PI:
Yolanda Colson, MD, Brigham and Women's Hospital

Site-responsible Investigators:

Brigham and Women's Hospital: Onkar Khullar, MD, 617-732-8695,

Eligibility Criteria

Inclusion Criteria: - Suspected or histologically documented new non-small cell carcinoma that have agreed to undergo a thoracotomy for segmentectomy, lobectomy, bilobectomy or pneumonectomy as recommended by their thoracic surgeon for treatment - Surgically resectable lung cancer - N2 lymph nodes negative on PET scan or mediastinoscopy - Age > or equal to 18 years of age - Men, women of non-child bearing age or women with a negative pregnancy test Exclusion Criteria: - Patient does not want to undergo subsequent surgical resection - Medical condition such as uncontrolled infection or cardiac disease that, i the opinion of the treating surgeon, makes resection unreasonably hazardous for the patient. - T4 or N2 disease - Pre-operative spirometry that suggests they cannot undergo resection of their primary tumor by segmentectomy, lobectomy, bilobectomy, or pneumonectomy - Iodide or seafood allergy - Pregnant or lactating women
  •   Email
  •   Print
  •   Share
  • Make an Appointment

    • For adults:
      877-442-3324 (877-442-DFCI)

    • Quick access:
      Appointments as soon as the next day for new adult patients

    • For children:
      888-733-4662 (888-PEDI-ONC)

    • Make Appointment Online